SLC5A2 and type 2 diabetes mellitus: A meta-analysis published by McGuire et al., showed improved cardiovascular and renal outcomes in type 2 diabetes patients on SGLT2 inhibitors, making it a drug of choice in patients with heart failure [24] and renal failure [25].